1. Home
  2. CNXC vs NTLA Comparison

CNXC vs NTLA Comparison

Compare CNXC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$25.51

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$11.57

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXC
NTLA
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
CNXC
NTLA
Price
$25.51
$11.57
Analyst Decision
Strong Buy
Buy
Analyst Count
5
23
Target Price
★ $54.80
$20.02
AVG Volume (30 Days)
1.6M
★ 3.5M
Earning Date
03-24-2026
05-07-2026
Dividend Yield
★ 5.79%
N/A
EPS Growth
N/A
★ 27.43
EPS
★ 1.20
N/A
Revenue
★ $9,825,771,000.00
$67,671,000.00
Revenue This Year
$5.29
N/A
Revenue Next Year
$2.49
$62.75
P/E Ratio
$21.21
★ N/A
Revenue Growth
2.15
★ 16.92
52 Week Low
$19.12
$7.95
52 Week High
$49.37
$28.24

Technical Indicators

Market Signals
Indicator
CNXC
NTLA
Relative Strength Index (RSI) 40.78 42.51
Support Level $25.33 $11.51
Resistance Level $26.39 $13.88
Average True Range (ATR) 1.88 0.57
MACD -0.54 -0.06
Stochastic Oscillator 21.56 18.66

Price Performance

Historical Comparison
CNXC
NTLA

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: